RIO DE JANEIRO, BRAZIL - Brazill health regulator Anvisa on Wednesday allowed resumption of late-stage clinical trials for China’s Sinovac COVID-19 vaccine, which had been suspended due to the death of a study subject that was registered in São Paulo as a . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here